Why choose ValiRx Animal Health

Everything we do is guided by our five core values: ethical innovation, translational impact, smart development, scientific integrity and collaboration expertise.

Ethical innovation
Translational impact
Smart development
Scientific integrity
Collaboration expertise
A great Dane with their head out the car window

Ethical Innovation

We advance veterinary medicine through scientifically rigorous, ethically responsible development that prioritises better outcomes for companion animals while supporting broader translational progress.

Scientists working in a lab

Translational impact

We bridge veterinary and human medicine through comparative science, accelerating clinically meaningful discoveries that benefit both animal patients and future human therapies.

Close-up of transparent bubbles of various sizes with a dark red and purple blurred background.

Smart developement

We use intelligent, data-driven development strategies to reduce attrition, accelerate decision-making, and maximise scientific and commercial value to bring the right treatments to patients in need.

A cat relaxing at home

Scientific integrity

We maintain credibility, transparency, and precision in everything we do, ensuring our work is grounded in robust evidence and real-world relevance.

A dog is sitting in a park surrounded by leaves

Collaboration expertise

We work with leading scientific, clinical, and commercial partners to combine expertise, challenge thinking, and deliver stronger outcomes together.

Close-up of a microscope lens with colorful blue and red lighting in a lab setting.

First-in-class
veterinary Oncology

Through our work at ValiRx and Inaphaea, we have established a pipeline of first-in-class veterinary oncology assets for companion animals, underpinned by strong translational relevance to human cancer therapies. By applying translational models throughout development, we accelerate clinical insight, reduce risk, and increase the potential for successful commercialisation.

How we work

We work alongside vets, pet parents and partners to translate comparative oncology into meaningful new treatments for animals and better outcomes for pets.

Meet the team

Michelle from ValiRx

Michelle Barnard​

Chief Scientific Officer

For me, this only works if it’s done ethically, and that’s non-negotiable. Get that right, and the science can make a real difference for animals and humans alike.

Mark from ValiRx

Dr Mark Eccleston

Managing Director

I’ve seen first-hand how few treatment options exist for pets with cancer, and I’m determined to change that offering hope for patients and returns for our investors.

Melissa from ValiRx

Melissa Barr

Chief Operating Officer​

I believe that comparative oncology isn’t just about good science – it also means pets and people benefit from the same breakthroughs

Advisory board

Dr Heather Wilson Robles

  • Veterinary Oncologist​
  • Vice President of Research at Ethos Discovery​
  • Former President of Veterinary Cancer Society​
  • Former Clinical Professor at Texas A&M with research interests including clinical research using dogs as a model for paediatric cancer​

Dr Simon Wheeler

  • Independent Animal Health and Veterinary Consultant​
  • Managing Director Veterinary Neurology Ltd​
  • Former Head of Commercial and External Relations, Global Marketing at Novartis Animal Health​
  • Former Manging Director Novartis Venture Fund​

What our partners say

Hear from the veterinary professionals and research partners working with us to make cancer care more accessible for companion animals.

Having a treatment option we can offer earlier in the pathway has changed the conversations we have with owners. It gives families a realistic choice at the point where they need it most, rather than asking them to decide between aggressive intervention and doing nothing at all.

Placeholder One
Placeholder One
Veterinary Oncologist, Referral Practice

What stood out to us was how straightforward it was to integrate into an existing clinic workflow. There was no specialist equipment to buy and no lengthy retraining, which matters enormously for a practice of our size and caseload.

Placeholder Two
Placeholder Two
Practice Principal, Small Animal Clinic

The team's approach to evidence has been genuinely rigorous. They have been open about what the data does and does not yet show, and that transparency is what gave us the confidence to take part in the work at all.

Placeholder Three
Placeholder Three
Clinical Research Lead

For our clients, cost has always been the barrier that ends the conversation. Being able to offer something accessible without compromising on the standard of care is the single biggest change we have seen in years.

Placeholder Four
Placeholder Four
Head Veterinary Nurse